Bone Biologics Corporation (BBLG) Investor Relations Documents

Bone Biologics Corporation (BBLG) investor relations documents from the company's IR site: 2 presentations, 16 press releases; latest deck 2026-08-18. Read in-app with summaries. First-party data.

Investor Presentation — Bone Biologics (BBLG) presents NELL-1, a regenerative medicine for bone, targeting the $3B spine fusion market with a clear regulatory path and strong IP.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-18PresentationInvestor Presentation
2026-08-12Press releaseBone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
2026-07-23Press releaseBone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
2026-06-23PresentationInvestor Presentation
2026-05-19Press releaseBone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
2026-01-08Press releaseRead More >
2025-12-23Press releaseRead More >
2025-09-03Press releaseRead More >
2025-06-30Press releaseRead More >
2025-06-27Press releaseRead More >
2024-10-21Press releaseRead More >
2024-09-09Press releaseRead More >
2024-08-02Press releaseRead More >
Press releaseBURLINGTON, Mass. (September 3, 2025) (more…)
Press releaseBURLINGTON, Mass. (June 26, 2025) — Bone Biologics Corporation (“Bone Biologics” or the “Company”) (more…)
Press releaseBURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) (more…)
Press releaseBURLINGTON, Mass. (September 4, 2025) – (more…)
Press releaseBURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) (more…)

BBLG overview · BBLG earnings · BBLG financials · BBLG KPIs · BBLG ownership · BBLG peers · BBLG filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.